key: cord-1006492-yh5j7bup
authors: Rachow, Tobias; Lamik, Toni; Kalkreuth, Jana; Kurze, Stephanie; Wagner, Kathleen; Stier, Pia; Hammersen, Friedrich J.; Rüthrich, Maria Madeleine; Winkelmann, Nils; Klink, Anne; Hilgendorf, Inken; Hermann, Beate; Lang, Susanne; Hochhaus, Andreas; von Lilienfeld‐Toal, Marie
title: Detection of community‐acquired respiratory viruses in allogeneic stem‐cell transplant recipients and controls—A prospective cohort study
date: 2020-07-23
journal: Transpl Infect Dis
DOI: 10.1111/tid.13415
sha: 8861f4e2ec5552ea7ad5a4d3ff1e6f857b3864de
doc_id: 1006492
cord_uid: yh5j7bup

BACKGROUND: Community‐acquired respiratory viruses (CARV) cause upper and lower respiratory tract infections (URTI/LRTI) and may be life‐threatening for recipients of an allogeneic stem cell transplantation (allo‐SCT). METHODS: In a prospective study encompassing 4 winter‐seasons, we collected throat gargles (TG) at random time points from allo‐SCT recipients (patients) and controls and followed them up for at least 3 weeks including repetitive sampling and documentation of symptoms. A Multiplex‐PCR system to identify 20 CARV and Mycoplasma pneumoniae was used to detect CARV. RESULTS: One hundred ninety‐four patients with 426 TG and 273 controls with 549 TG were included. There were more patients with a positive test result (25% vs 11% in the controls), and the patients had a higher number of positive TG (70 = 16%) compared to controls (32 = 6%) (P < .001). Altogether, 115 viruses were detected. Multiple viruses in one TG (11/48, 34%) and prolonged shedding were only observed in patients (13/48, 27%). Patients had more RSV (18/83, 26%) and adenovirus (15/83, 21%) than controls (both viruses 2/32, 6%). Independent risk factors for the detection of CARV included age >40 years (OR 3.38, 95% CI 1.8‐6.4, P < .001) and presence of URTI‐symptoms (OR 3.22, 95% CI 1.9‐5.5, P < .001). No controls developed a LRTI or died whereas 4/48 (8%) patients developed a LRTI (coronavirus in 2, RSV in 1 and influenza A H1N1 in 1 patient). One patient died of CARV (influenza A H1N1). CONCLUSION: Allo‐SCT‐recipients have more CARV‐infections, exhibit a different epidemiology, have more cases of co‐infection or prolonged shedding and have a higher rate of LRTI and mortality.

Community-acquired respiratory viruses (CARV) are increasingly recognized as clinically relevant pathogens. They commonly cause symptoms of upper respiratory tract infection (URTI) such as cough and running nose. URTI is often harmless, but in some cases pave the way for bacterial superinfection and cause lower respiratory tract infection (LRTI) which can be fatal. 1 Usually, the term CARV comprises orthomyxoviridae (influenza A, B, and C), paromyxoviridae (including parainfluenza 1-4 (PIV), respiratory syncytial virus A and B (RSV), and human metapneumovirus (hMPV)), coronaviridae, picornaviridae (including >100 different serotypes of rhinovirus and enterovirus), adenoviridae, polyomavirus type 1, and bocavirus. Some of them like influenza or RSV follow seasonal patterns whereas others such as rhinovirus and PIV can be detected throughout the whole year. [2] [3] [4] The epidemiology of CARV has attracted growing attention with the broad use of nuclear-acid amplification techniques. The increased sensitivity of PCR-based methods created more positive findings than culture-based and serological methods. Commercially available multiplex-test systems are increasingly used in routine clinical practice. However, the clinical relevance of the identification of CARV in samples from the respiratory tract is not entirely clear. In a patient with symptoms of URTI, the CARV are assumed to be the cause-if detected. Little is known about the true pathogenicity of CARV and about the natural course of the infection. In cancer patients, asymptomatic carriers and long-term viral shedding have been described, 5, 6 whereas this seems to be rare in healthy persons. 7 Clinical symptoms caused by different CARV may vary-for example, influenza is usually assumed to be the cause of febrile illnesses during the winter months, whereas rhinoviruses are more associated with common colds. However, symptoms are not specific for a defined CARV.

All CARV have been reported to cause fatalities in severely immunosuppressed patients. 8 For patients after allogeneic stem-cell transplantation (allo-SCT), contact with friends and family carries the risk of attracting CARV infections. One of the main goals of patient management after successful allo-SCT is to return to a normal life situation, where the avoidance of CARV exposure may be difficult to achieve, 9 particularly as there are only few data on healthy asymptomatic individuals and the risk they may pose.

This prospective study addresses the question of epidemiology of CARV in allo-SCT recipients compared with otherwise non-immunocompromised controls. In addition, risk factors for CARV infection, symptoms of CARV infection and the course of the disease were analyzed. We hypothesize that allo-SCT recipients and non-immunocompromised controls have different incidences and a different clinical course of CARV infections.

This study was a prospective cohort trial including allo-SCT recipients (patients) and controls. It was approved by the local institutional review board (Nr 3891-09/13) and is in part registered in the German Clinical Trials Registry (DRKS00005367, cohort healthy persons only). The study was initially designed to analyze controls for 2 consecutive winter seasons and was amended after 1 year to include patients as well. After 3 years, the recruitment of controls was extended for a third winter season ( Figure 1 ).

During the winter months from 2013/2014 till 2016/2017, we collected throat gargles (TG) from patients and controls at random time points after they had given their written informed consent.

Patients were recruited in the outpatient clinic of the stem cell transplantation program during routine visits. Controls were recruited among students, among members of a choir and among patients without any immunosuppression attending preoperative routine visits prior to elective minor surgical procedures such as cholecystectomy, glaucoma surgery, or orthopedic interventions. TG were collected at least twice at a 3-week interval independently of symptoms. In addition, patients and controls were questioned regarding their lifestyle and possible symptoms at the time of collection of TG. An additional questionnaire was completed approximately 1-2 weeks after the last TG to account for any symptoms that may have developed in the meantime.

were recruited in the outpatient clinic of the stem cell transplantation program during routine visits; controls were recruited amongst students, members of a choir and among patients without any immunosuppression undergoing minor surgical procedures such as elective cholecystectomy, glaucoma surgery or orthopedic interventions, recruitment was independent of whether or not the patient presented with symptoms of a CARVinfection Most participants with a positive TG complained of symptoms (Table 3 ). Very few positive TG (6/102, 6%) were not associated with any symptoms. Except for fever, which was significantly more common in people suffering from influenza, no other symptom was significantly different for any of the viruses. In general, the symptoms were consistent with an URTI. LRTI was observed in 4/48 (8%) patients with a positive test for CARV but not in controls. Coronavirus was found in 2, RSV in 1 and influenza A H1N1 in 1 patient, who died. factor whereas GvHD or time after allo-SCT were not associated with a higher risk (Table 4 and data not shown). a Not all patients provided answers to all questions, most patients had more than one symptom. 

In this prospective study of patients after allo-SCT and controls, we found a higher rate of positivity for CARV in TG from patients compared with controls. Interestingly, age was associated with a higher rate of positivity in controls but not in patients. Also, despite a gen- We were surprised to find an increased risk of CARV in subjects of higher age. It is known that children exhibit the highest risk, 10 but the higher risk of elderly people is increasingly recognized. [11] [12] [13] Of note, the effect of age appears to be unique to the healthy population, since it could not be confirmed as independent risk factor in our patients, consistent with other studies. 14 Also, the risk may start earlier than previously assumed. 10 Our data suggest that an age of 40 years and above was associated with an increased risk whereas others have only investigated the age over 65. 10 Typical symptoms proved to be the most relevant risk factor for the presence of CARV, consistent with previous findings from other groups. 15, 16 However, similar to others we could not find a specific pattern of symptoms for a specific virus with the possible exception of fever, which was most common in influenza infection. 15 . .99 a URTI-Symptoms included cough, running nose, sore throat, and fever.

friends with children in the household and supports the opportunity to a faster return to normal life after allo-SCT.

The potentially most relevant finding of our study is the different epidemiology of CARV in patients after allo-SCT versus healthy individuals. Especially with regard to the latter group, there is a general lack of available data. To the best of our knowledge, there is no study to date comparing these two populations prospectively in the same regional and seasonal setting. In the literature, RSV appears to be more common in allo-SCT-recipients than in otherwise healthy people with a reported incidence of 16%-18% 5,14 in allo-SCT-recipients versus 2%-4% 7,18 in the general population.

This pattern is reflected in our study population with 26% RSV in patients versus 6% RSV in controls. Three patients were tested positive within 1 week which suggests an RSV outbreak in our outpatient clinic of the stem cell transplantation program. Such outbreaks are well described in the literature. [19] [20] [21] However, this occurred in the middle of the typical season (springtime 2015) and

clinically there was no reason to suspect an outbreak. It is therefore unlikely that an undetected outbreak is the sole reason for the different epidemiology.

In most studies, influenza appears to be the most prominent CARV in the general population; however, they usually include symptomatic people only 4,7,18,22-24 and did not always test for coronaviruses. 24 Yet, coronaviruses were by far the most common CARV detected in our controls. It may be that they are often underdiagnosed because coronaviruses are often not tested for. Our data suggest that coronaviruses account for a large proportion of common colds, similar to rhinoviruses. In contrast, adenoviruses which are also frequently left out in testing panels seem to play a minor role in healthy adults. In patients on the other hand, they appear to be In contrast to others, we did not detect any bocaviruses, parechoviruses, Mycoplasma, and only very few hMPV in patients or in controls. 25 This may be a sampling error due to the design of the study since these pathogens do not exhibit such a strict seasonality as influenza and RSV and we only sampled during the winter months. 26 Alternatively, they play a minor role in our setting in the healthy population as well as in patients. Since CARV-infection requires human contact it seems likely that there are significant regional variations and it seems prudent to acquire knowledge regarding the local epidemiology.

Not surprisingly, our study confirmed the potential of long viral shedding in cancer patients as described previously. 6, 27 Reassuringly, we did not detect any shedding in controls, which supports the practice of stopping contact isolation after resolution of symptoms in otherwise healthy people without the need for a negative test. In cancer patients, however, our study confirms the need for re-testing to be able to declare a patient free of virus. 8 Generally, infections with CARV can be potentially dangerous even in non-immunosuppressed people. 28 However, the higher rate of complications, especially LRTI, in cancer patients has been well described. 1, 29 In the literature, the rate of LRTI is assumed to be around 25% with an associated mortality of 30%. 8 In the patient group, the rate of LRTI was 8%, which is lower than expected, but the associated mortality was 25% which is consistent with published data. In our study, we did not observe any LRTI or fatal course in controls. The low rate of LRTI may be due to the fact that patients were assessed at random time-points and not only triggered by relevant clinical symptoms and we therefore detected more CARV-infections (less severe) than would have been detected in routine clinical practice.

In conclusion, allo-SCT recipients have more CARV-infections and exhibit a different epidemiology than controls with more RSV and adenovirus. Although we did not find an association with obvious immunosuppression or GvHD, this may still be a symptom of a suppressed immune system. In addition, patients have a more complicated course with more cases of co-infection and prolonged shedding as well as a higher rate of LRTI and mortality. Prolonged viral shedding was not observed in non-immuno-suppressed controls. Risk factors for the detection of a CARV are age >40 years and symptoms typical for URTI.

Open access funding enabled and organized by Projekt DEAL.

The authors declare no conflict of interests. 

The study was approved by the local institutional review board (Nr 3891-09/13) in 2013.

https://orcid. org/0000-0002-9756-3541

Influenza virus infections in patients with malignancies -characteristics and outcome of the season 2014/15. A survey conducted by the Infectious Diseases Working Party (AGIHO) of the German Society of Haematology and Medical Oncology (DGHO)

Respiratory syncytial virus and parainfluenza virus

Parainfluenza virus infections after hematopoietic stem cell transplantation: risk factors, response to antiviral therapy, and effect on transplant outcome

Comparison of viral infection in healthcare-associated pneumonia (HCAP) and community-acquired pneumonia (CAP)

Epidemiology of viral respiratory tract infections in an outpatient haematology facility

Long-term shedding of influenza virus, parainfluenza virus, respiratory syncytial virus and nosocomial epidemiology in patients with hematological disorders

Aetiology of lower respiratory tract infection in adults in primary care: a prospective study in 11 European countries

Community acquired respiratory virus infections in cancer patients-Guideline on diagnosis and management by the Infectious Diseases Working Party of the German Society for haematology and Medical Oncology

Community-acquired respiratory viruses in transplant patients: diversity, impact, unmet clinical needs

Epidemiology of viral respiratory infections in a tertiary care centre in the era of molecular diagnosis

Seasonal incidence of medically attended respiratory syncytial virus infection in a community cohort of adults >/=50 years old

Respiratory infections in elderly people: viral role in a resident population of elderly care centers in Lisbon

Epidemiology of respiratory pathogens among elderly nursing home residents with acute respiratory infections in Corsica

Viral respiratory tract infections in allogeneic haematopoietic stem cell transplant recipients in the era of molecular testing

Incidence and outcomes of respiratory viral infections in lung transplant recipients: a prospective study

Upper and lower respiratory tract viral infections and acute graft rejection in lung transplant recipients

Infection prevention and control in health-care facilities in which hematopoietic cell transplant recipients are treated

Systematic review of respiratory viral pathogens identified in adults with community-acquired pneumonia in Europe

Nosocomial transmission of respiratory syncytial virus in an outpatient cancer center

Detection and control of a nosocomial respiratory syncytial virus outbreak in a stem cell transplantation unit: the role of palivizumab

Risk factors and containment of respiratory syncytial virus outbreak in a hematology and transplant unit

Impact of respiratory viruses in hospital-acquired pneumonia in the intensive care unit: a single-center retrospective study

Frequency of respiratory viruses among patients admitted to 26 Intensive Care Units in seven consecutive winter-spring seasons (2009-2016) in Northern Italy

The frequency and seasonality of influenza and other respiratory viruses in Tennessee: two influenza seasons of surveillance data

Regional, age and respiratory-secretion-specific prevalence of respiratory viruses associated with asthma exacerbation: a literature review

Prevalence of respiratory viruses among adults, by season, age, respiratory tract region and type of medical

Comparison of respiratory virus shedding by conventional and molecular testing methods in patients with haematological malignancy

Acute myocardial infarction after laboratory-confirmed influenza infection

The natural history of influenza infection in the severely immunocompromised vs nonimmunocompromised hosts